(0272–0316) RA – Treatment Poster I

Saturday, November 12, 2022

1:00 PM – 3:00 PM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

1:00 PM – 3:00 PM Eastern Time

Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
Abstract Poster Presenter: Daniel Aletaha, MD, MS, MBA – Medical University Vienna
1:00 PM – 3:00 PM Eastern Time

An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
Abstract Poster Presenter: Kevin Winthrop – Oregon Health & Science University
1:00 PM – 3:00 PM Eastern Time

Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Abstract Poster Presenter: Sabina Ciciriello, MD – Melbourne Health
1:00 PM – 3:00 PM Eastern Time

Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Abstract Poster Presenter: Maya Buch, MD, PhD – University of Manchester
1:00 PM – 3:00 PM Eastern Time

Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
Abstract Poster Presenter: James Galloway, MBBS – King's College London
1:00 PM – 3:00 PM Eastern Time

Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
Abstract Poster Presenter: Xavier Mariette, MD – Université Paris-Saclay
1:00 PM – 3:00 PM Eastern Time

The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
Abstract Poster Presenter: Patrick Durez, MD – UCLouvain
1:00 PM – 3:00 PM Eastern Time

Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
Abstract Poster Presenter: Alejandro Balsa, MD – Hospital Universitario La Paz
1:00 PM – 3:00 PM Eastern Time

Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
Abstract Poster Presenter: Maya Buch, MD, PhD – University of Manchester
1:00 PM – 3:00 PM Eastern Time

Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Abstract Poster Presenter: Maya Buch, MD, PhD – University of Manchester
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
1:00 PM – 3:00 PM Eastern Time

The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Abstract Poster Presenter: Nobuyuki Yajima, MD, PhD, MPH – Showa-Universtiy of Medicine
1:00 PM – 3:00 PM Eastern Time

Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Abstract Poster Presenter: Daniela Oliveira, MD – Unicamp
1:00 PM – 3:00 PM Eastern Time

Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Abstract Poster Presenter: Roberto Caporali, MD – Universita statale di Milano
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
Abstract Poster Presenter: Grace C. Wright, MD, PhD, FACR – Grace C Wright MD PC
1:00 PM – 3:00 PM Eastern Time

Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Abstract Poster Presenter: Christina Charles-Schoeman, MD, MS – UCLA Medical Center
1:00 PM – 3:00 PM Eastern Time

Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Abstract Poster Presenter: Loïc Meudec, MD – Université Paris-Saclay
1:00 PM – 3:00 PM Eastern Time

Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Abstract Poster Presenter: Song-Chou Hsieh – National Taiwan Unuversity Hospital
1:00 PM – 3:00 PM Eastern Time

Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the "JAK-pot" Study)
Abstract Poster Presenter: Kim Lauper, MD – Geneva University Hospitals
1:00 PM – 3:00 PM Eastern Time

Tofacitinib Leads to Significant Weight Gain - A Real Life Experience of 429 Patients
Abstract Poster Presenter: Naga Prabu, Sr, MD, DM – SAKTHI RHEUMATOLOGY CENTRE PVT LTD
1:00 PM – 3:00 PM Eastern Time

Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Poster Presenter: Andrea Rubbert-Roth, MD – Cantonal Hospital St Gallen
1:00 PM – 3:00 PM Eastern Time

Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Abstract Poster Presenter: Ronald F. Van Vollenhoven, MD, PhD – Amsterdam UMC
1:00 PM – 3:00 PM Eastern Time

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
1:00 PM – 3:00 PM Eastern Time

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Abstract Poster Presenter: Gerd Burmester, MD – EULAR
1:00 PM – 3:00 PM Eastern Time

Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors
Abstract Poster Presenter: Yusuke Miyazaki, MD, PhD – The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
1:00 PM – 3:00 PM Eastern Time

Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
1:00 PM – 3:00 PM Eastern Time

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
1:00 PM – 3:00 PM Eastern Time

Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Abstract Poster Presenter: Yoshiya Tanaka, MD, PhD – University of Occupational and Environmental Health, Japan
1:00 PM – 3:00 PM Eastern Time

Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Abstract Poster Presenter: Mohamed-Eslam Mohamed, PhD – AbbVie
1:00 PM – 3:00 PM Eastern Time

Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
Abstract Poster Presenter: Klaus Krüger, MD – Rheumatologisches Praxiszentrum München
1:00 PM – 3:00 PM Eastern Time

Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
Abstract Poster Presenter: Se Rim Choi, MD – Seoul National University
1:00 PM – 3:00 PM Eastern Time

Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICE^TM) Database
Abstract Poster Presenter: Allan Gibofsky, MD, JD – Hospital for Special Surgery
1:00 PM – 3:00 PM Eastern Time

Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
1:00 PM – 3:00 PM Eastern Time

Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
Abstract Poster Presenter: Ho So, MD – The Chinese University of Hong Kong
1:00 PM – 3:00 PM Eastern Time

Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Poster Presenter: Scott Stryker, MD, MPH, DrPH – Amgen, Inc
1:00 PM – 3:00 PM Eastern Time

Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Abstract Poster Presenter: Chahin Pachai, PhD – Bristol Myers Squibb
1:00 PM – 3:00 PM Eastern Time

Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Abstract Poster Presenter: Joseph F. Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
1:00 PM – 3:00 PM Eastern Time

Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Abstract Poster Presenter: Eugen Feist, MD – Helios Department of Rheumatology
1:00 PM – 3:00 PM Eastern Time

Higher Baseline Circulating CD4⁺CXCR5⁺PD-1^hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
Abstract Poster Presenter: Ting Wang, MD, PhD – University of Washington
1:00 PM – 3:00 PM Eastern Time

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
Abstract Poster Presenter: Ajay Aggarwal, MD – Aclaris Therapeutics, Inc.
1:00 PM – 3:00 PM Eastern Time

Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Abstract Poster Presenter: Jay Chatfield, MPH – Kiniksa Pharmaceuticals
1:00 PM – 3:00 PM Eastern Time

Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Abstract Poster Presenter: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
1:00 PM – 3:00 PM Eastern Time

Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Abstract Poster Presenter: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
1:00 PM – 3:00 PM Eastern Time

The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Abstract Poster Presenter: Josef Smolen, MD – Medical University of Vienna
1:00 PM – 3:00 PM Eastern Time

Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis
Abstract Poster Presenter: Christine Landlinger-Schubert, PhD – OncoOne R&D